About Bachem
Bachem is a Swiss-based company that has been at the forefront of peptide and oligonucleotide development for over 50 years. The company's commitment to innovation and quality has made it a leader in the industry, with a reputation for excellence that is recognized worldwide.
At Bachem, the focus is on developing high-quality peptides and oligonucleotides that meet the needs of researchers, scientists, and pharmaceutical companies around the world. The company's products are used in a wide range of applications, including drug discovery, diagnostics, and therapeutics.
One of Bachem's key strengths is its ability to provide customized solutions to meet specific customer needs. With state-of-the-art facilities located in Switzerland and California, Bachem has the expertise and resources to develop peptides and oligonucleotides tailored to individual requirements.
In addition to its core business of peptide synthesis, Bachem also offers a range of related services such as analytical testing, process development, and GMP manufacturing. This comprehensive approach ensures that customers receive end-to-end support throughout their projects.
Bachem's commitment to quality is evident in every aspect of its operations. The company adheres strictly to international standards for quality management systems (ISO 9001) as well as environmental management systems (ISO 14001). In addition, all products undergo rigorous testing before they are released for sale.
The company's success can be attributed not only to its technical expertise but also its strong customer focus. Bachem prides itself on building long-term relationships with customers based on trust and mutual respect. This approach has helped the company establish itself as a trusted partner in peptide synthesis across multiple industries.
Looking ahead, Bachem remains committed to driving innovation in peptide synthesis while maintaining its reputation for excellence in quality and customer service. With an experienced team of scientists dedicated to advancing research through cutting-edge technology platforms like CRISPR/Cas9 gene editing tools or mRNA vaccines production capabilities - there’s no doubt that this innovative-driven firm will continue leading advancements within this field!